Newcastle-based life sciences company LightOx has been chosen by NATO to develop its light-activated wound treatment technology for frontline use. The firm's innovative molecule is designed to combat antibiotic-resistant bacteria, offering a promising new way to treat injuries both in military settings and civilian healthcare.